A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis
Phase of Trial: Phase IV
Latest Information Update: 30 Nov 2018
At a glance
- Drugs Apremilast (Primary)
- Indications Cardiovascular disorders; Plaque psoriasis
- Focus Therapeutic Use
- Acronyms VIP-A
- 26 Nov 2018 Planned End Date changed from 1 Jan 2020 to 1 Jan 2021.
- 26 Nov 2018 Planned primary completion date changed from 1 Mar 2019 to 1 May 2020.
- 31 Aug 2018 Biomarkers information updated